JP2023551480A - ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 - Google Patents
ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 Download PDFInfo
- Publication number
- JP2023551480A JP2023551480A JP2023532339A JP2023532339A JP2023551480A JP 2023551480 A JP2023551480 A JP 2023551480A JP 2023532339 A JP2023532339 A JP 2023532339A JP 2023532339 A JP2023532339 A JP 2023532339A JP 2023551480 A JP2023551480 A JP 2023551480A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- substituted
- moiety
- oral pharmaceutical
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200163362 | 2020-11-27 | ||
| KR10-2020-0163362 | 2020-11-27 | ||
| PCT/KR2021/017802 WO2022114908A1 (ko) | 2020-11-27 | 2021-11-29 | 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023551480A true JP2023551480A (ja) | 2023-12-08 |
| JPWO2022114908A5 JPWO2022114908A5 (https=) | 2024-11-28 |
| JP2023551480A5 JP2023551480A5 (https=) | 2024-11-28 |
Family
ID=81756220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532339A Pending JP2023551480A (ja) | 2020-11-27 | 2021-11-29 | ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240000803A1 (https=) |
| EP (1) | EP4252781A1 (https=) |
| JP (1) | JP2023551480A (https=) |
| KR (1) | KR20220075189A (https=) |
| CN (1) | CN116940384A (https=) |
| AU (2) | AU2021385222B2 (https=) |
| CA (1) | CA3200351A1 (https=) |
| GB (1) | GB2616223B (https=) |
| IL (1) | IL303023A (https=) |
| MX (1) | MX2023006189A (https=) |
| WO (1) | WO2022114908A1 (https=) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006523663A (ja) * | 2003-04-15 | 2006-10-19 | アクセス リミテッド | 高分子の取り込み |
| US20110257084A1 (en) * | 2008-02-25 | 2011-10-20 | Sungkyunkwan University | Exendin derivative linked biotin, method for the preparation thereof and pharmaceutical composition comprising the same |
| JP2014527801A (ja) * | 2011-09-01 | 2014-10-23 | ユニバーシティ オブ サザン カリフォルニア | ハイスループットペプチドミメティックを調製するための方法、経口バイオアベイラブルな薬物およびそれを含有する組成物 |
| JP2016530221A (ja) * | 2013-06-18 | 2016-09-29 | トランスジーン バイオテック リミテッド | 生物学的活性成分の経口送達のための医薬製剤及び方法 |
| WO2019087083A2 (en) * | 2017-10-31 | 2019-05-09 | Medimmune, Llc | Oral delivery of glp-1 peptide analogs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569901B2 (en) * | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
| KR20080042045A (ko) * | 2005-05-23 | 2008-05-14 | 에스디지,인코포레이티드 | 포유동물로의 인터페론 전달용 지질 구조물 |
| PL1767545T3 (pl) * | 2005-09-22 | 2010-04-30 | Biocompatibles Uk Ltd | Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy |
| US8962015B2 (en) * | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| CN102037008B (zh) * | 2008-03-18 | 2016-08-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、酰化胰岛素类似物 |
| AU2014364589B2 (en) * | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| KR20180039726A (ko) * | 2015-09-04 | 2018-04-18 | 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 | 인슐린 면역글로불린 융합 단백질 |
-
2021
- 2021-11-29 IL IL303023A patent/IL303023A/en unknown
- 2021-11-29 US US18/039,184 patent/US20240000803A1/en active Pending
- 2021-11-29 GB GB2309252.1A patent/GB2616223B/en active Active
- 2021-11-29 JP JP2023532339A patent/JP2023551480A/ja active Pending
- 2021-11-29 KR KR1020210167781A patent/KR20220075189A/ko active Pending
- 2021-11-29 WO PCT/KR2021/017802 patent/WO2022114908A1/ko not_active Ceased
- 2021-11-29 CN CN202180092430.9A patent/CN116940384A/zh active Pending
- 2021-11-29 EP EP21898733.7A patent/EP4252781A1/en active Pending
- 2021-11-29 CA CA3200351A patent/CA3200351A1/en active Pending
- 2021-11-29 MX MX2023006189A patent/MX2023006189A/es unknown
- 2021-11-29 AU AU2021385222A patent/AU2021385222B2/en active Active
-
2025
- 2025-08-27 AU AU2025223792A patent/AU2025223792C9/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006523663A (ja) * | 2003-04-15 | 2006-10-19 | アクセス リミテッド | 高分子の取り込み |
| US20110257084A1 (en) * | 2008-02-25 | 2011-10-20 | Sungkyunkwan University | Exendin derivative linked biotin, method for the preparation thereof and pharmaceutical composition comprising the same |
| JP2014527801A (ja) * | 2011-09-01 | 2014-10-23 | ユニバーシティ オブ サザン カリフォルニア | ハイスループットペプチドミメティックを調製するための方法、経口バイオアベイラブルな薬物およびそれを含有する組成物 |
| JP2016530221A (ja) * | 2013-06-18 | 2016-09-29 | トランスジーン バイオテック リミテッド | 生物学的活性成分の経口送達のための医薬製剤及び方法 |
| WO2019087083A2 (en) * | 2017-10-31 | 2019-05-09 | Medimmune, Llc | Oral delivery of glp-1 peptide analogs |
Non-Patent Citations (3)
| Title |
|---|
| FRIESEN,H.J. ET AL: "Novel maleimido-biotins for the selective biotinylation of sulfhydryls", PROTIDES OF THE BIOLOGICAL FLUIDS, vol. 34, JPN6024021474, 1986, pages 43 - 46, ISSN: 0005734718 * |
| SERENA SINGH ET AL., BIOCHEMISTRY, vol. 55, no. 20, JPN6024021473, 5 May 2016 (2016-05-05), pages 2875 - 2882, ISSN: 0005734717 * |
| SU YOUNG CHAE ET AL., BIOCONJUGATE CHEMISTRY, vol. 19, no. 1, JPN6024021468, 14 December 2007 (2007-12-14), pages 334 - 341, ISSN: 0005734716 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021385222A1 (en) | 2023-06-22 |
| US20240000803A1 (en) | 2024-01-04 |
| MX2023006189A (es) | 2023-07-04 |
| AU2021385222B2 (en) | 2025-05-29 |
| GB2616223A9 (en) | 2024-06-05 |
| KR20220075189A (ko) | 2022-06-07 |
| AU2025223792C1 (en) | 2025-10-16 |
| AU2025223792C9 (en) | 2026-01-22 |
| GB2616223A (en) | 2023-08-30 |
| EP4252781A1 (en) | 2023-10-04 |
| CA3200351A1 (en) | 2022-06-02 |
| GB2616223B (en) | 2026-03-18 |
| WO2022114908A1 (ko) | 2022-06-02 |
| IL303023A (en) | 2023-07-01 |
| CN116940384A (zh) | 2023-10-24 |
| AU2025223792A1 (en) | 2025-10-02 |
| AU2021385222A9 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200046725A1 (en) | Prodrug Comprising a Drug Linker Conjugate | |
| US7153930B1 (en) | Peptide transport | |
| JP5907999B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| CZ308395A3 (en) | Complex for b12 vitamin reception, process of its preparation, compositions containing thereof and its use | |
| JP2015536314A (ja) | 成長ホルモン送達のための脂肪酸アシル化アミノ酸 | |
| KR102480393B1 (ko) | 비오틴 모이어티와 결합된 생리활성 물질 및 이를 포함하는 경구 투여용 조성물 | |
| JP2025065438A (ja) | ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物 | |
| JP2023551480A (ja) | ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体の経口製剤 | |
| RU2860768C2 (ru) | Пероральный состав конъюгата биологически активного материала, содержащего фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним | |
| CN120981479A (zh) | Gip/glp1/gcg三受体激动剂及其用途 | |
| JP2023553362A (ja) | ビオチン部分、脂肪酸部分またはその組合せを連結されて有する生物学的活性材料結合体 | |
| RU2854617C2 (ru) | Конъюгат биологически активного материала, содержащий фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним | |
| HK40100062A (en) | Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto | |
| RU2798085C9 (ru) | Пролекарство, содержащее саморасщепляемый линкер |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20241120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260309 |